Impact of Hyperuricemia on Psoriatic Arthritis

NCT06125444 | Unknown

• 1 other identifier: 7957
• Study Type: observational
• Target: 242
• Locations: 1 country
• Sites: 1

Brief Summary

Psoriatic arthritis and gout (linked to hyperuricemia) are two rheumatisms well known to rheumatologists. There are epidemiological and physiopathological arguments in favor of a non-fortuitous link between these two rheumatisms, which to date has not been established. There is currently no recommendation to treat hyperuricaemia without an episode of gout attack. We hypothesize that there is a link between hyperuricemia and severity of rheumatism. This would ultimately modify the therapeutic management of hyperuricemic patients followed for psoriatic arthritis.

Conditions

Psoriatic Arthritis

Keywords

Psoriatic Arthritis; Hyperuricemia; Rheumatisms

Outcome Measures

Primary Outcomes (1)

• Retrospectively determine the impact of hyperuricemia on the response to psoriatic arthritis treatments: inventory of the latest treatments in progress and the response to treatment according to the treating rheumatologist

  Files analysed retrospectively from January 01, 2009 to December 31, 2019 will be examined

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Major subject (≥18 years old), with a history of psoriatic arthritis objectified according to the CIM 10-1 coding for patients followed in hospitalization at the HUS and HCC and subject presenting psoriatic arthritis objectified during a consultation by an HCC rheumatologist

You may qualify if:

• Major subject (≥18 years old)
• Subject with a history of psoriatic arthritis objectified according to the CIM 10-1 coding for patients followed in hospitalization at the HUS and HCC
• Subject presenting psoriatic arthritis objectified during a consultation by an HCC rheumatologist
• Among these two populations, all subjects for whom at least one serum uric acid assay was available in the medical file
• Subject having not expressed, after being informed, opposition to the reuse of their data for research purposes

You may not qualify if:

• Subject who expressed their opposition to participating in the study
• Subject under guardianship or curatorship
• Subject under safeguard of justice

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Rhumatologie - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Arthritis, Psoriatic; Hyperuricemia

Condition Hierarchy (Ancestors)

Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Arthritis; Joint Diseases; Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Renaud FELTEN, MD

CONTACT

33 3 88 12 79 64; renaud.felten@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 14, 2022
• First Posted: November 9, 2023
• Study Start: August 24, 2020
• Primary Completion: December 1, 2023
• Study Completion: December 31, 2023
• Last Updated: December 8, 2023

Record last verified: 2023-12

Locations

FR (1)